BPC-157 (Body Protection Compound-157)
BPC-157 is a synthetic peptide derived from a protective protein found in human gastric juice. It has shown strong tissue-healing properties across tendons, ligaments, muscles, the gut lining, and the nervous system in animal studies. Researchers have studied it extensively for inflammatory bowel conditions, joint injuries, and post-surgical recovery, though human clinical trials remain limited.
FormBlends Peptide Context
Reviewed May 14, 2026BPC 157 peptide guide should help a reader move from broad search interest to specific verification. When the topic touches peptide therapy, the important details are evidence quality, clinical fit, contraindications, pricing, pharmacy transparency, and follow-up support. Use this page to decide what to ask next rather than treating it as personal medical advice.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
BPC-157 authority snapshot
BPC-157 is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Meaningful evidence with limits
Regulatory reality
Reinstated for compounding (Feb 2026)
Safety screen
Nausea at higher doses, Mild dizziness, Injection site redness or irritation should be reviewed in context.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for BPC-157?
BPC-157 should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- BPC-157
- Category
- Recovery
- Evidence
- Meaningful evidence with limits
- FDA status
- Not FDA approved
Step 1
Check evidence level
BPC-157 has over 100 published animal studies showing consistent tissue-healing effects, but only 3 small human trials have been completed. The animal data is unusually strong and consistent across injury types, which is why researchers keep coming back to it. Still, the lack of large-scale human trials means we can't call the evidence definitive yet.
Review evidenceStep 2
Screen safety context
Nausea at higher doses, Mild dizziness, Injection site redness or irritation should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessRecovery evidence hub
BPC-157 needs evidence language that does not overpromise
BPC-157 attracts intense search demand because people connect it with tendon, joint, gut, and injury recovery. The opportunity is to be more useful than hype pages: explain the biological rationale, the limits of human evidence, what is preclinical, what is anecdotal, and what a clinician would need to rule out before someone considers any peptide pathway.
Decision question for BPC-157
Is the reader dealing with a diagnosed injury or gut issue that needs medical workup before peptide discussion?
Peptide evidence layer
Evidence read
Strong BPC-157 content should name the gap between mechanistic animal research and human decision-making. It should also route people toward diagnosis, imaging, physical therapy, medication review, and quality verification instead of treating the peptide as a cure-all.
Safety watch
The main risk is skipping a real evaluation for tendon rupture, inflammatory bowel disease, infection, medication interactions, or an injury that needs imaging, procedure, or rehabilitation.
Conversion fit
The right next step is a provider review that starts with the problem, not the product. BPC-157 should be discussed only after diagnosis, goals, source quality, and realistic expectations are clear.
Last updated: April 6, 2026
Typical Dosage
250-500 mcg per day, typically split into two doses. Some protocols use up to 750 mcg daily for acute injuries.
Administration
Subcutaneous injection, Oral capsule, Intramuscular injection
Typical Cost
$100-250/month
FDA Status
Not FDA Approved
Half-Life
Approximately 4-6 hours (estimated from animal data)
Onset of Action
Effects on healing markers visible within 24-72 hours in animal models. Clinical improvement in human ulcer trials seen within 1-2 weeks.
Bioavailability
High oral bioavailability compared to most peptides, which is unusual. Animal studies show systemic effects from oral dosing.
About BPC-157
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide fragment derived from a larger protein called BPC, which the human body naturally produces in gastric juice. Its molecular weight is 1,419.53 Da, and its CAS number is 137525-51-0. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. What makes BPC-157 unusual among peptides is its stability. Most peptides break down quickly in stomach acid, but BPC-157 remains active when taken orally. A 2001 study in the Journal of Physiology (PMID: 11547844) tested oral BPC-157 in patients with active gastric and duodenal ulcers and found dose-dependent healing over 4 weeks, with no serious side effects reported. The research base for BPC-157 is large but lopsided. Over 100 animal studies have been published since the mid-1990s, covering injuries to tendons, ligaments, muscles, nerves, the gut lining, the liver, and even the brain. The consistency across these studies is striking: BPC-157 accelerated healing in nearly every tissue type tested. A 2021 study in the Journal of Orthopaedic Surgery and Research (DOI: 10.1186/s13018-021-02632-x) confirmed faster tendon-to-bone healing with measurable improvements in collagen organization. But here is the honest picture: only 3 small human trials have been completed, totaling fewer than 50 participants. The first, published in Current Pharmaceutical Design in 2003 (PMID: 12769738), tested BPC-157 in inflammatory bowel disease patients. Results were positive, but the sample size was small. Two other trials looked at ulcer healing with similar limitations. The mechanism behind BPC-157's effects involves multiple pathways. It promotes angiogenesis (new blood vessel formation) through upregulation of VEGF and FGF receptors. It modulates the nitric oxide system, which controls blood flow and inflammation at injury sites. It also interacts with the dopaminergic system, which may explain early reports of mood-related benefits in animal models. BPC-157 was one of the 14 peptides reinstated for legal compounding in February 2026 following the HHS reclassification. Before that announcement, its availability through compounding pharmacies had been uncertain since late 2023, when the FDA added several peptides to its restricted list. Lyophilized BPC-157 should be stored at -20C before reconstitution. Reconstitute with bacteriostatic water by directing the stream against the vial wall and swirling gently. Do not shake. Once reconstituted, store at 2-8C and use within 28 days. The peptide is stable at pH 3-8 in solution.
How BPC-157 Works
BPC-157 works by promoting angiogenesis, which is the formation of new blood vessels in damaged tissue. It upregulates growth factor receptors including VEGF and FGF, accelerating the repair cascade at injury sites. It also modulates the nitric oxide system and has demonstrated protective effects on the gut-brain axis through interactions with the dopaminergic and serotonergic systems.
Receptor targets:
Benefits
- Accelerates healing of tendons, ligaments, and muscle tears
- Supports gut lining repair and reduces intestinal inflammation
- Promotes new blood vessel formation at injury sites
- Reduces inflammation throughout the body
- May protect against NSAID-induced gut damage
- Supports nerve regeneration and neuroprotection
- Shown to heal skin wounds and burns faster in animal models
- May counteract the negative GI effects of certain medications
What Does the Research Say?
BPC-157 has over 100 published animal studies showing consistent tissue-healing effects, but only 3 small human trials have been completed. The animal data is unusually strong and consistent across injury types, which is why researchers keep coming back to it. Still, the lack of large-scale human trials means we can't call the evidence definitive yet.
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease
Current Pharmaceutical Design, 2003 · DOI · PubMed
Early human trial in IBD patients showed BPC-157 improved symptoms at multiple dose levels without serious adverse events
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
Molecules, 2014 · DOI · PubMed
BPC-157 directly upregulated growth hormone receptor expression in tendon cells, explaining one pathway behind its healing effects
BPC 157 and its relationship with nitric oxide system
Current Pharmaceutical Design, 2014 · DOI · PubMed
Demonstrated BPC-157 modulates the nitric oxide system bidirectionally, blocking both excess and insufficient NO production at injury sites
Stable gastric pentadecapeptide BPC 157 heals established gastric and duodenal ulcers and chronic erosive gastritis
Journal of Physiology, 2001 · PubMed
Human trial in patients with active ulcers showed dose-dependent healing with no significant side effects over 4-week treatment
PubMed evidence trail
Research sources used to frame this page
For BPC-157, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
Potential Side Effects
- Nausea at higher doses
- Mild dizziness
- Injection site redness or irritation
- Headache in some users
- Fatigue reported occasionally
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| NSAIDs (ibuprofen, naproxen) | BPC-157 may offset the GI damage caused by chronic NSAID use. Some practitioners use them together specifically for this reason. | minor |
| Corticosteroids | BPC-157's healing pathways may work against the tissue-thinning effects of chronic steroid use. Theoretical interaction, not studied directly. | moderate |
Who Is BPC-157 For?
Women
No sex-specific contraindications identified in published research. Some practitioners report similar efficacy across men and women for gut and joint healing protocols.
Adults Over 50
Healing timelines may be longer in older patients due to baseline angiogenesis decline. No dose adjustment data available, but some practitioners start at lower doses (200 mcg/day) in patients over 60.
Athletes
Popular in sports medicine for tendon and ligament repair. Not currently on WADA's prohibited list, but athletes should verify status with their governing body before use.
Regulatory Status
FDA Approved
No
Compounding Legal
Yes
2026 HHS Status
Reinstated for compounding (Feb 2026)
BPC-157 was one of the 14 peptides reinstated for compounding in February 2026 following the HHS reclassification. Before that, its compounding status was in a gray area after FDA restrictions in late 2023.
Last verified: 2026-04-06
Stacking Options
BPC-157 is commonly stacked with the following peptides for enhanced results:
Conditions Addressed
Get BPC-157 from FormBlends
Pharmaceutical-grade bpc-157 with free physician consultation.
View Product DetailsFind a BPC-157 Clinic Near You
Browse peptide therapy clinics in your area that offer bpc-157 treatments.
Find Peptide Clinics